Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
Evaluating the synergistic effect of MG1 infection and SMAC mimetic treatment on latently HIV-infected cells
FY 2021-22
Summary
Human immunodeficiency virus (HIV) primarily infects immune cells. This results in weakened immune function with the inability to fight infection, and if left untreated, HIV can develop into AIDS. There is no cure for HIV as this virus can incorporate itself into the host cells DNA and establish a lifelong latent infection. While in this latent state, the immune system cannot recognize the virus, and latently infected cells still carry HIV DNA. Current treatments including combined antiretroviral therapy (cART) are unable to cure HIV because it cannot eliminate HIV entirely from the body and there is immune failure following their discontinuation due to viral activation of latently infected cells. This is one of the main reasons that the latent reservoir is recognized as a major barrier to curing HIV infection. Latent HIV-infected cells are more susceptible to killing by Maraba virus (MG1), an oncolytic virus (OV), compared to healthy cells because of defects in their signalling pathway which MG1 can selectively target. To further enhance MG1 killing, another potential therapy is SMAC mimetics (SM). SM are small molecules which inhibit inhibitors of apoptosis proteins, inducing cell death. Since SM have shown promising effects when combined with OV, it is possible that a synergistic treatment of MG1 and SM can enhance the killing of latently HIV-infected cells. Hence, combination therapy with MG1 and SM will be tested to determine if they can mediate selective killing of cells latently infected with HIV. Currently, there are 38 million people living with HIV and this project offers a novel cure strategy by employing a combination treatment to selectively eradicate latently HIV-infected cells.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
466687
Name
Ameeriar Yasmeen
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Evaluating the synergistic effect of MG1 infection and SMAC mimetic treatment on latently HIV-infected cells
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Apoptosis; Cd4+ T-Cell; Hiv; Hiv Latency; Hiv Reservoir; Maraba Virus; Mg1; Oncolytic Virus; Smac Mimetics
Abstract
Human immunodeficiency virus (HIV) primarily infects immune cells. This results in weakened immune function with the inability to fight infection, and if left untreated, HIV can develop into AIDS. There is no cure for HIV as this virus can incorporate itself into the host cells DNA and establish a lifelong latent infection. While in this latent state, the immune system cannot recognize the virus, and latently infected cells still carry HIV DNA. Current treatments including combined antiretroviral therapy (cART) are unable to cure HIV because it cannot eliminate HIV entirely from the body and there is immune failure following their discontinuation due to viral activation of latently infected cells. This is one of the main reasons that the latent reservoir is recognized as a major barrier to curing HIV infection. Latent HIV-infected cells are more susceptible to killing by Maraba virus (MG1), an oncolytic virus (OV), compared to healthy cells because of defects in their signalling pathway which MG1 can selectively target. To further enhance MG1 killing, another potential therapy is SMAC mimetics (SM). SM are small molecules which inhibit inhibitors of apoptosis proteins, inducing cell death. Since SM have shown promising effects when combined with OV, it is possible that a synergistic treatment of MG1 and SM can enhance the killing of latently HIV-infected cells. Hence, combination therapy with MG1 and SM will be tested to determine if they can mediate selective killing of cells latently infected with HIV. Currently, there are 38 million people living with HIV and this project offers a novel cure strategy by employing a combination treatment to selectively eradicate latently HIV-infected cells.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ameeriar, Yasmeen
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~